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Key messages / Clinical implications 46 
- Nasal epithelial transcriptome changes in response to ason  47 
- Pollen allergen immunotherapy (AIT) alters expression of asthma, chemokine signaling, and 48 
toll like receptor signaling related genes 49 
- AIT increases microbial community diversity 50 
- RNA-sequencing enables integrated analysis of microbe and host transcriptomes  51 
 52 
Capsule summary 53 
Nasal epithelial transcriptome is altered by the season. Birch pollen allergen immunotherapy recovers 54 
microbial community diversity and alters expression of allergy related genes.  55 
 56 
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To the Editor, 63 
Airway epithelial cells are known to have an important role in allergic rhinitis (AR) (1-3). They 64 
constitute the first line of defense against inhaled a roallergens and are active mediators of innate and 65 
adaptive immune responses (3). Their aberrant functioning is linked with an intake of allergens (2) and 66 
their transcriptome is reprogrammed under exposure to pollens (2-3) as well as in AR (3) and atopic 67 
asthma (1). Furthermore, epithelial cells interact with and are involved in generating an environmental 68 
niche for the respiratory microbiota, whose imbalance has been associated with seasonal AR (4) and 69 
childhood rhinitis and asthma (5). However, the precis  functions of epithelial host cells and respiratory 70 
microbes in AR are still largely elusive, especially during pollen allergen immunotherapy (AIT) that is 71 
associated with symptom reduction (6), decrease in allergen-specific biomarkers, and altered T- and B-72 
cell responses (7). 73 
We collected nasal brushings for RNA-sequencing from five healthy subjects and three 74 
birch pollen AR patients with and without AIT at two springs and winters and studied seasonal, AR, 75 
and AIT-related alterations in the nasal epithelial and microbial transcriptomes (Fig 1, A, Fig E1, Table 76 
E1). Pollen count and AR symptom information was alo assessed, revealing the presence of high 77 
amounts of birch pollen at spring samplings (Fig 1, B) and a marked improvement of quality of life in 78 
AR subjects with AIT compared to controls (p-value < 0.005) and AR subjects without AIT (p-value < 79 
0.03) but not between other groups (Fig 1, C). 80 
RNA-sequencing resulted in 90 million mappable reads per sample on average. Of all the 81 
annotated human protein-coding genes, 17,347 were dduced expressed and 360 differentially 82 
expressed between different timepoints within groups and between different groups within timepoints 83 
(Fig 2, G). Identified were also 166 (Fig 2, A and B) and 17 (Fig 2, D and E) protein-coding genes with 84 
an altered expression between the consecutive spring  a d winters, respectively. Notably, we identified 85 
the greatest transcriptional reprogramming between springs in the AR-AIT group, indicating that AIT 86 
alters epithelial expression in the presence of allergens. Analyses also revealed three allergy related 87 













in AR-noAIT subjects, whereas TLR (Toll like receptor) and chemokine signaling pathways were both 89 
affected in AR-noAIT and AR-AIT subjects (Fig 2, C,and Fig E2). Pathway enrichment analysis of 90 
winter data revealed pathways with coordinated exprssion change only in healthy controls (Fig 2, F). 91 
Analysis of expressed variants pinpointed in turn eight variants expressed in two or more AR subjects 92 
at some time point but in none of the healthy controls (Fig E3).  93 
Further analysis of the gene expression profiles of the three allergy pathways between the 94 
spring samplings highlighted marked similarities in the AR-AIT and control groups that were not seen 95 
in the AR-noAIT group (Fig E2). These results imply that AIT may restores epithelial gene expression 96 
towards normal and indicate that effectivity of AIT could be screened from nasal epithelium in addition 97 
to leukocytes. Specifically, the MHCII components were up-regulated at the second spring in AR-AIT 98 
and control but not in the AR-noAIT group (Fig E2, A), indicating that AIT restores the compromised 99 
antigen-presenting capacity of epithelial cells in AR. We also found that genes that are downstream 100 
effectors of the chemokine signaling or pattern recognition and provide proinflammatory, antiviral, 101 
chemotactic, and T-cell stimulatory effects behaved alike between the AR-AIT and control groups (Fig 102 
E2 B, C). These findings are in line with the findigs that changes in expression of TLR genes are 103 
associated with allergic rhinitis and suggest a role f r TLR agonists in treatment of AR (3, 7). Notably, 104 
expression of several asthma related genes was found t  be in opposite between the AR-AIT and AR-105 
noAIT subjects (Fig E2). 106 
 Microbial classification of sequencing data was performed to explore whether AR alters 107 
nasal microbiota (archaeal, bacterial, and viral) and whether AIT could restore microbial imbalances 108 
towards normal. On average, ~500 CPMs (~16,340 read-pairs) per sample were assigned to microbial 109 
taxa, 98.13% of which received a genus-level classification (Fig E4, A). The classification showed that 110 
bacteria, archaea, and viruses were part of the active nasal microbiota, the most common genera being 111 
Bacillus (average abundance 42.23%), Methanocaldococcus (average abundance 35.72%), and 112 
Alpharetrovirus (average abundance 4.32%). Similar to previous studies (8), a large sample-to-sample 113 
variation was observed (Fig E4, A). Particularly, six samples taken at the second spring varied greatly 114 
from the rest (Fig E4, A and E4, B) and were, for instance, the drivers of the greater abundance of 115 
viruses at the second spring compared to the other tim points (Fig 2, H). Interestingly, examination of 116 
changes in species abundancies (Fig E4, C) pinpointed Pseudomonas aeruginosa to be more abundant 117 













We also computed alpha diversities to evaluate the effect of AR and AIT on the microbial 119 
diversity of nasal epithelia (Fig E5-E7, A-N). This analysis revealed that control subjects primarily had 120 
the highest alpha diversity, differing from that seen previously in a study on seasonal allergic rhinitis 121 
(4) but similar to that focusing on children with asthma and rhinitis (5). Interestingly, majority of the 122 
diversity indices suggested an increase of diversity between the first and second winter in all groups. 123 
Most prominent the increase was in the AR-AIT group, while some increase was also detectable in the 124 
control and AR-noAIT groups (Fig E6, A-N). The diversity at the second winter in the AR-AIT group 125 
also changed more towards that of the control group than what was the corresponding change in the 126 
AR-noAIT group (Fig E6, A-N). These findings are largely in line with the previous studies noting that 127 
the bacterial diversity varies during allergy season (4) and suggest that AIT may increase microbial 128 
diversity and restore it towards normal. 129 
 Limitations of this study include the small subject number, lack of placebo group, 130 
differences in baseline allergic symptoms between the groups, differences in pollen seasons, 131 
differences in air quality, and technical differencs in sampling, which may in part have compromised 132 
results. Yet, the study provided interesting insights into the epithelial transcriptome during AIT and 133 
revealed that AIT causes subtle but significant alter tions in asthma, TLR signaling, and chemokine 134 
signaling related genes and may as well recover micobiological diversity towards normal. Seasonal 135 
heterogeneity represented the largest source of variation in transcriptomes, indicating a need for novel 136 
biomarkers in AIT treatment monitoring that accommodate inherent heterogeneity and seasonal 137 
variation. 138 
 139 
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Figure legends 191 
 192 
 193 
FIG 1. Study overview. A) Study flow chart showing number of subjects, sampling points, and the 194 
start of the AIT. Samples were collected at four consecutive sampling points from five healthy control 195 
subjects and six AR subjects. Three patients with AR started AIT. All subjects were without 196 
medication for at least four weeks before sampling. I  springs, symptomatic AR patients were without 197 
antihistamines for at least three days prior to sampling. B) Counts of birch and total pollen during the 198 
course of the study in grey and black, respectively. Counts of other pollens than birch were under 199 
detection level during sampling during the spring samplings. There were no counts of pollen in the air 200 
during the winter samplings. C) Total visual analogue scale (VAS) symptom score at the day of 201 
sampling. Control and AR-AIT groups (p-value < 0.005) as well as AR-AIT and AR-noAIT groups (p-202 
value < 0.023) differed in interaction by two-way repeated measures analysis of variance (ANOVA). 203 
Statistically significant interaction were not observed between control and AR-noAIT groups at the 204 














FIG 2. Overview of RNA-sequencing data. A and D) Protein-coding genes statistically differentially 207 
expressed (Q-value ≤ 0.1 and absolute log2 fold-change ≥ 1.5) between spring (A) and winter (D). The 208 
heatmap was drawn using log2 (+1 offset) counts per million expression values, mean centered and 209 
scaled by gene averages. Red indicates up-regulation of the gene and blue down-regulation of the gene 210 
relative to the average. B) and E) Venn diagrams show  the total number of differentially expressed 211 
genes between spring (B) and winter (E) sampling points at each group. C) and F) KEGG pathways 212 
enriched among differentially expressed genes per group. Shades of blue and red indicate significance 213 
of the enrichment and size of the dot represent gene count. Listed at the bottom in brackets is the total 214 
number of differentially expressed genes in each group with an association to some KEGG pathway. G) 215 
Number of differentially expressed genes in selected-pairwise comparisons. Comparisons not shown 216 
are: AR-noAIT Nov2 vs. AR-noAIT May1 (52), AR-AIT Nov2 vs. AR-AIT May1 (1), AR-AIT May1 vs. 217 
AR-noAIT May1 (7), AR-AIT Nov1 vs. AR-noAIT Nov1 (0), AR-AIT May2 vs. AR-noAIT May2 (6), 218 
AR-AIT Nov2 vs. AR-noAIT Nov2 (1), Control May2 vs. Control May1 (27), Control Nov2 vs. Control 219 
May1 (7), and Control Nov2 vs. Control Nov1 (17). H) Relative abundances of microbial (archaeal, 220 
bacterial, and viral) genera and average microbial load per group. Only genera accounting for >5% of 221 
the total microbial load in any group are shown. The line denotes the average number of microbe-222 
classified reads within the group. 223 
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AIT: allergen immunotherapy 29 
AR: Allergic rhinitis 30 
CPM: Count per million 31 
DAVID: Database for Annotation, Visualization, and Integrated Discovery 32 
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KEGG: Kyoto Encyclopedia of Genes and Genomes 34 
PcoA: Principal coordinates analysis 35 
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Materials and methods 50 
 51 
Subjects  52 
Study subjects were recruited from Skin and Allergy Hospital of Helsinki University Hospital. The 53 
study plan was approved by the ethical committee of H spital District of Helsinki and Uusimaa, 54 
Finland (permission number19/13/003/00/11). Written informed consent was received from all subjects 55 
and their parents if the age of the participant was under 18-years. The study has been registered in 56 
ClinicalTrials.com (nro. NCT01985542). Baseline data of the study subjects is shown in Table E1. The 57 
total number of participants entering the study was23 (Fig E1). AR-AIT group received SCIT in Nov 58 
2011 after the second sampling visit (Fig 1, Fig E1), meaning that two samplings of the AR-AIT group 59 
were performed before and two during AIT. 60 
 61 
Nasal brushings and RNA extraction 62 
Nasal epithelial brushing was performed to middle matus of both sides of nasal cavity after slight 63 
blowing of nose without local anesthesia as described (1). Epithelial cells were collected at four time 64 
points, washed once with ice cold nuclease free PBS, and resuspended immediately into RNAlater 65 
RNA stabilization reagent (Qiagen, Hilden, Germany) to preserve RNA profiles. The epithelial RNA 66 
isolation was done next day using Qiagen RNeasy Mini K t with the optional DNAse treatment 67 
included. 68 
 69 
Library preparation and RNA sequencing 70 
Agilent Bioanalyzer RNAnano chip (Agilent) was used to evaluate the integrity of RNA and Qubit 71 
RNA –kit (Life Technologies) to quantitate RNA in epithelial cell samples. If acceptable in quality 72 
(RIN value >7), 1.0 ug of total RNA sample was ribodepleted and prepared to RNA sequencing library 73 
by using ScriptSeq v2™ Complete kit (Illumina, Inc., San Diego, CA, USA). RNA sequencing libraries 74 
were purified with SPRI beads (Agencourt AMPure XP, Beckman Coulter, Brea, CA, USA). The 75 
library QC was evaluated on High Sensitivity chips by Agilent Bioanalyzer (Agilent). Paired-end 76 
sequencing of sequencing libraries with 100 bp read length was performed using Illumina HiSeq 77 
technology (HiSeq 2000, Illumina, Inc., San Diego, CA, USA). Planned read amount was 40 million 78 















RNA sequencing data processing 82 
RNA sequencing data were preprocessed as described previously (2). Briefly, Trimmomatics (3) was 83 
used to correct read data for low quality, Illumina adapters, and short read-length. Filtered paired-end 84 
reads were aligned to the human genome (GRCh38) using the STAR (4) with the guidance of 85 
EnsEMBL v82 gene models. Default 2-pass per-sample parameters were used, except that the overhang 86 
on each side of the splice junctions was set to 99. The alignments were then sorted and PCR duplicates 87 
were marked using Picard, feature counts were computed sing SubRead (5), feature counts were 88 
converted to expression estimates using Trimmed Mean of M-values (TMM) normalization (6), and 89 
lowly expressed genomic features with counts per million (CPM) value ≤1.00 in less than half of 90 
controls or birch-pollen patients were removed. Default parameters were used, with exception that 91 
reads were allowed to be assigned to overlapping geom  features in the feature counting.  92 
 93 
Host gene expression analysis 94 
Differential expression testing was performed using the edgeR (7) software and included testing of 95 
differential expression between and within groups at different sampling points. In the statistical testing, 96 
comparisons between subject groups used a combined factor of subject group and sampling point, 97 
while comparisons within subject groups employed also  factor for the subject. The resulting p‐values 98 
were adjusted Storey’s Q-value approach with significance defined as Q-value ≤0.10. A cut-off of 99 
absolute log2 fold-change of ≥ 1.5 and EnsEMBL v82 biotype annotations were used as additional 100 
filters to select differentially expressed genes (DEGs) with protein coding annotation for the 101 
downstream analysis. Heatmaps of differentially expr ssed protein coding genes were produced with 102 
pheatmap R package (8). Hierarchical clusters (HC) were generated using the spearman correlation and 103 
ward.D2 as the linkage method, with the exception of using ward.D2 and Euclidean distance for genes 104 
that were differentially expressed between different sampling years at springs and using complete 105 
linkage and spearman correlation for genes that were differentially expressed between different 106 
sampling years at winters. Counts per million (CPMs) data were used to generate heatmaps. Venn 107 
diagrams were generated using the VennDiagram R package (9). Functional profiles of differentially 108 
expressed genes were investigated with clusterProfiler (10) using functions enrichGO and 109 
enrichKEGG. Outputs of enrichment analyses were visualized using dotplot function in clusterProfiler. 110 













(11). In the process, KEGG gene IDs of the selected pathways were fed along with log2 fold-change 112 
values from relevant comparisons. Color codes on the pathway map were used to illustrate genes that 113 
were differentially expressed and the direction of their expression changes. Fold-change values beyond 114 
that range were truncated to the closest extreme, i.e. values >2 were truncated to 2, and values < -2 115 
truncated to -2. Downstream analyses were performed using R 3.3.1 with Bioconductor 3.0. 116 
 117 
Variant analysis  118 
Transcript variants were called from STAR alignments using the GATK best practices workflows for 119 
transcriptome data (12) and then annotated using Annovar (13) as defined previously (2). Quality 120 
control analyses were performed as defined previously (2). Variant calls were further filtered by 121 
accepting only those that were present in two or moe AR cases, not present in any control case, and 122 
predicted to be pathogenic by various pathogen prediction methods part of the Annovar (13) annotation 123 
tool. Heatmap was plotted using pheatmap. The functio al effects of variants were taken from Annovar 124 
(13) outputs. Additionally, we also plotted barplot using CPM expression value of genes in healthy 125 
control and AR groups. 126 
 127 
Microbial community profiling 128 
Microbial community profiling was performed as previously described (14) with some modifications. 129 
Specifically, RNA-sequencing data were preprocessed for adapter trimming, low quality bases filtering, 130 
and removal of reads less than 36 bp in length by using Trimmomatic (3). Paired-end reads passing the 131 
pre-processing were mapped against rRNA sequences from RFAM (15) v12.3 using the Burrows-132 
Wheeler Aligner (BWA) (16) with default settings and reads matching rRNAs were filtered by using 133 
samtools (17). Centrifuge (18) was then used to classify paired-end reads to microbial taxa. Alignment 134 
data were converted to kraken-style output. In the classification, reads were aligned against 27,127 135 
known complete bacterial, archaeal, and viral genome assemblies, the human genome, and 10,615 136 
technical artifact sequences that were available in the RefSeq (19) database at February 2018. Default 137 
parameters were used, with the exception that only e (i.e. the lowest common ancestor) assignment 138 
was reported for read-pairs with multiple primary assignments. Taxa having <100 read-pairs assigned 139 
to them in any sample were removed. Pairwise comparisons between and within groups at different 140 
sampling points were performed by applying DeSeq2 (20) on the number of reads covered by the clade 141 













method, comparisons between subject groups were don usi g a combined factor of subject group and 143 
sampling point, and comparisons within subject groups with a model where individuals were nested 144 
within subject groups. Each taxonomic level was analyzed separately and variance stabilizing 145 
transformation (VST) was used to generate expression estimates for heatmap visualizations. The 146 
Storey’s Q-value adjustment (21) was used to correct data for multiple hypothesis testing, with 147 
significance defined as Q-value ≤0.05. Finally, alpha diversity (Observed, Chao1, ACE, Shannon, 148 
Simpson, InvSimpson, and Fisher), beta diversity (Bray-Curtis dissimilarity), and rarefaction analyses 149 
were done using the Phyloseq software (22) applied on number of reads assigned directly to the given 150 




General  155 
AR subjects, and especially AR-AIT cases, had higher total median S-IgE, birch specific S-IgE, and 156 
SPT wheel diameter to birch and symptom scores during samplings (Table E1, Fig 1). AR-AIT group 157 
reported benefit (Fig 1) and reported no severe sid-effects at the end of SCIT three years after start of 158 
SCIT (data not shown).  159 
 160 
Transcriptome of nasal epithelium  161 
We generated in total of 5164 million raw paired-end transcript reads. Manual inspection of the quality 162 
plots generated using FASTQ indicated that sequencing data was of excellent quality. On average, 90 163 
million reads were mapped to the reference per subject. Mapped reads were then used to generate CPM 164 
expression estimates, revealing expression of 13,873 protein coding genes among healthy controls and 165 
17,347 across all the 44 samples. Altogether, expression of 34,896 genes were found. To gain insight 166 
into cellular processes dysregulated in AR and AIT, differentially expressed genes between sample 167 
groups were identified using edgeR (7). In this analysis, we identified altogether 360 genes to be 168 
differentially expressed with the Q-value ≤ 0.1 and absolute log2 fold change ≥ 1.5 between different 169 
timepoints within group and between different groups within timepoints. 170 
 171 













Comparison of the transcriptome profiles between the springs revealed 119 DEGs between the 173 
samplings in the AR-AIT group, 49 between the samplings in the AR-noAIT group, and 27 between 174 
the samplings in healthy controls (Fig 2, B), which suggest that greatest transcriptional reprogramming 175 
took place in AR-AIT group followed by AR-noAIT group and healthy subjects. Comparison of the 176 
two consecutive winters revealed only 17 DEGs among healthy controls and none among AR patients, 177 
suggesting that AIT alters epithelial expression only in the presence of allergens (Fig 2, E).  178 
 179 
Differential expression of immune response and signaling pathways 180 
We performed KEGG pathway enrichment analysis to discover functional themes shared by DEGs. 181 
This analysis revealed altogether 21 KEGG pathways with coordinated expression change between the 182 
spring samplings (Fig 2, C). Out of these, 4 were associated with genes differentially expressed in AR-183 
AIT group, including the chemokine signaling and Toll-like receptor (TLR) signaling pathway (Fig 2, 184 
C). Genes differentially expressed in AR-noAIT group were in turn associated with 8 pathways, 185 
including IL-17 signaling and asthma pathway that were discovered only in this comparison (Fig 2, C). 186 
The healthy group genes were enriched in 11 KEGG pathways (Fig 2, C). Altogether we detected three 187 
allergy related pathways, of which asthma was discovered only in the AR-noAIT comparison and TLR 188 
signaling and chemokine signaling pathways were discovered in AR-noAIT and AR-AIT comparisons 189 
(Fig 2, C). Pathway enrichment analysis of winter comparison data revealed pathways with coordinated 190 
expression change only in healthy controls (Fig 2, F). 191 
 192 
In depth analysis of allergy related pathways 193 
Allergy-related pathways found in the pathway analysis (Fig E2) were analyzed more in-depth to study 194 
these mechanisms. Firstly, the asthma pathway consisted n total 3 DEGs. The AR-AIT group and 195 
healthy controls displayed upregulation of MHCII and downregulation of FcεRI at the second spring 196 
(Fig E2, A). The expression of various other members of the pathway was altered, although 197 
unsignificantly, between spring samplings (Fig E2, A). These more borderline findings included IL-13 198 
that is a T-cell-specific transcription factor and i terleukin (23), IL-4 that is IgE synthesis switch factor 199 
(23), and IL-5 that is an eosinophil growth factor (23). Expression of genes of the asthma pathway 200 
between timepoints occurred to opposite directions n AR-AIT and AR-noAIT groups (Fig E2, A). The 201 
second pathway of interest was TLR signaling pathway (Fig E2, B) consisting altogether 67 202 













happened to opposite directions in AR-AIT and AR-noAIT groups (Fig E2, B). The third pathway of 204 
relevance to AR was chemokine signaling pathway. This pathway consisted of 49 dysregulated genes 205 
(Fig E2, C), including various chemokines and chemokine receptors. Expression of genes between 206 
timepoints occurred to opposite directions in AR-AIT and AR-noAIT groups (Fig E2, C).  207 
 208 
Transcript variants expressed in AR patients  209 
The GATK best practice for RNA sequencing (12) was employed to identify expressed variants. This 210 
approach revealed altogether 3,268,177 (on average 74277 per subject) variants passing GATK filters. 211 
Removal of intronic and silent variants and polymorphisms resulted in 8,174 (on average 186 per 212 
subject) variants that were further narrowed down to 8 potential candidates expressed in at least two 213 
AR subjects at any time point but in none of the healt y control samples (Fig E3).  214 
 215 
Functional characterization of microbiome showed no AR related changes 216 
The effect of AR and AIT to the active nasal microbiota was studied by identifying microbial reads 217 
from the RNA sequencing data and performing microbial classification. On average ~16,340 read-pairs 218 
(500 CPMs) per sample were assigned to bacterial, achaeal, or viral taxa with a high sample-to-sample 219 
variation (minimum of 791 reads (24 CPMs) and maximum of 69,428 reads (1791 CPMs)). Of these 220 
microbial reads, on average ~98.13% were classified at genus-level and 67.08% at the species-level. 221 
The genus-level classifications (Fig 2, H and Fig E4) showed that overall the most abundant genera 222 
were Bacillus, Methanocaldococcus, and Alpharetrovirus, with average relative proportions of 223 
~42.23%, ~35.72%, and ~4.32%, respectively, other genera having average relative proportions of 224 
~1.57% (Acinetobacter) or less. The relative proportions of the detected g nera varied greatly between 225 
the samples, Bacillus demonstrating the greatest variation (relative propo tions ranging from 0% to 226 
~63.76%). The relative proportions of viruses, particularly Alpharetrovirus, was greater in the second 227 
spring sampling point than in the other sampling points for all the groups, whereas the relative 228 
proportion of Bacillus was reduced (Fig 2, H and Fig E4, A). This variation, however, was mainly 229 
driven by the second spring samples of six cases, who ere distributed among all groups (Fig E4, A). 230 
Examination of the community compositional differenc s between the samples revealed these six 231 
samples to be the most dissimilar from the rest, which, in turn, had rather similar community 232 
compositions (Fig E4, B). To further investigate microbial richness, we estimated the alpha diversity 233 













diversity for AR-AIT group when the second winter was compared to the first (Fig E6, A-N). Some 235 
change of diversity between second and first winters was also seen for the control group, while some 236 
indices indicated also an increase for the AR-noAIT group. The increase seen in AR-noAIT group was, 237 
however, less than that observed for the AR-AIT group. The second winter diversity indices of the AR-238 
AIT group were also mainly closer to those of the control group than the indices of the AR-noAIT 239 
group (Fig E6, A-N). Finally, examination of significant (Q-value ≤ 0.05) changes in species 240 
abundancies (Fig E4, C) revealed more changes in all groups between the two spring sampling points 241 
than between the winter sampling points. The winter comparisons revealed only increased species for 242 
the control and AR-AIT groups, whereas for the AR-noAIT group only decreased species were 243 
reported. The AR-AIT group had significantly less P eudomonas aeruginosa in the second spring 244 
sampling point than the first. For the other groups, the comparisons revealed no significant changes in 245 
the abundance of this bacterium.  246 
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Table E1. Baseline characteristics of the subjects. 314 
 315 
  All subjects  AR patients 
  Controls AR patients P-value  AR-noAIT AR-AIT P-value 
Baseline characteristics        
 No. of subjects 5 6   3 3  
 Age (y), median (IQR) 44 (39-48) 39 (34-46) .43  34 ( 2-42) 41 (39-43) .70 
 Men/women (n) 1/4 3/3 .54  2/1 1/2 1.00 
1Spirometry values (% predicted), median (IQR)         
 FEV1 baseline  107 (105-109) 95 (94-96) .23  96 (95-103) 97 (94-95) .30 
 FEV1 bronchodilation  110 (105-110) 97 (95-99) .39  97 (96-104) 97 (95-99) 1.00 
 FEV1/FVC ratio baseline  104 (101-104) 98 (98-103) .33  103 (101-107) 95 (92-98) .30 
 FEV1/FVC bronchodilation  105 (101-106) 102 (98-104) .55  104 (101-108) 99.5 (97-102) .40 
 PEF baseline  109 (102-125) 109 (101-110) .57  110 ( 06-116) 98 (87-109) .20 
 PEF bronchodilation  104 (92-125) 112 (92-114) .74  112 (102-113) 100.5 (86-115) 1.00 
Symptoms during sampling in spring1, median (IQR)        
 Total RQLQ score  0 (0-6) 48.5 (24-74) .019  40 (23-49) 74 (49-87) .40 
 Total VAS score 15 (10-36) 744 (358-1352) .009  217 (358-471) 1352 (1128-1512) .10 
Serum values in spring1, median (IQR)        
 Total IgE (kU/L) 9 (7-14) 61.5 (39-200) .015  39 (26-275) 72 (62-136) .70 
 Birch-specific IgE (kU/L) 0 (0-0) 16.4 (3.3-24.2) .004  12 (6-16) 24 (14-28) .40 
 Timothy-specific IgE (kU/L) 0 (0-0) 0 (0-0) .85  0 ( -45) 0 (0-0) 1.00 
SPT wheal diameter (mm), median (IQR)        
 Negative control 0 (0-0) 0 (0-0) 1.00  0 (0-0) 0 (0-0) 1.00 
 Histamine (positive control) 5 (5-5) 5 (5-5) 1.00  5 (5-5) 5 (5-5) 1.00 
 Birch pollen 0 (0-0) 5 (4-6) .004  4 (3.5-6) 5 (5-5.5) .60 
 Timothy grass pollen 0 (0-0) 0 (0-0) 1.00  0 (0-2.5) 0 (0-0) 1.00 
 Festuca pratensis pollen 0 (0-0) 0 (0-0) 1.00  0 (0-2.5) 0 (0-0) 1.00 
 Mugwort pollen 0 (0-0) 0 (0-0) 1.00  0 (0-2.5) 0 (0-0) 1.00 
 Cladosporium herbarum 0 (0-0) 0 (0-0) 1.00  0 (0-0) 0 (0-0) 1.00 
 Cat dander 0 (0-0) 0 (0-5) .46  0 (0-2.5) 0 (0-3) 1.00 
 Dog dander  0 (0-0) 0 (0-4) .46  0 (0-2) 0 (0-2.5) 1.00 
 Horse dander 0 (0-0) 0 (0-0) 1.00  0 (0-0) 0 (0-0) 1.00 
 Dermatophagoides pteronyssinus 0 (0-0) 0 (0-0) 1.00  0 (0-0) 0 (0-0) 1.00 
 316 
Diagnosis of allergic rhinitis (AR) was based on a typical history, skin prick test (SPT; ALK-Abello, 317 
Hørsholm, Denmark), total serum IgE, and serum birch and timothy allergen specific IgE antibodies. 318 
Healthy volunteers did not have symptoms and were ngative for SPT of common aeroallergens and 319 
serum birch and timothy allergen specific IgE antibodies. Exclusion criteria were: age under 12 years, 320 
use of tobacco products, nonallergic rhinitis, allergic rhinitis symptoms caused by other than seasonal 321 
allergens, asthma, and general disease requiring regular medication. Asthma was excluded by absence 322 
of typical symptoms and by normal values in spirometry with bronchodilation test. 1) One subject 323 













histamine challenge test. He had normal 15th percentile density (PD15) of Forced expiratory volume in 325 
1 second (FEV1) result instead of bronchodilation test. Questionnaire regarding baseline characteristics 326 
and symptoms was collected at each sampling visit. We used the 28-item Rhinoconjunctivitis Quality 327 
of Life Questionnaire (RQLQ) (25). Subjects filled visual analogue scale (VAS) so that they were 328 
without medication. The questionnaire included 18 questions concerning airway symptoms and 23 329 
questions concerning general health. Value 0 (mm) indicated no symptoms and value 100 (mm) 330 
indicated the worst case. The total maximum score of the 41 questions was 4,100. In the analysis, VAS 331 
scores ≤ 3 mm were regarded as 0. P-values were computed by Kruskal-Wallis and Mann Whitney U-332 



































Figures legends 356 
 357 
FIG E1. Flowchart of the study. The total number of participants entering the study was 23. Initially, 358 
seven allergic rhinitis (AR) patients were assigned with pollen allergen immunotherapy (AIT; AR-AIT 359 
group) and nine others to the conventional therapy (AR-noAIT group). The study also included seven 360 
control subjects (control group) without allergy. One participant in the AR-AIT group discontinued the361 
study before starting AIT due to a diagnosis of a cardiac disease requiring surgery. The other 362 
participants in the AR-AIT group fulfilled the whole AIT scheme of three years with the total dose over363 
2,000.000 SQ (standardized quality). AIT was performed according to standard 3-year protocol or 364 
normal 3-year scheme (26). Subcutaneous injections of birch pollen extract (Betula verrucosa, ALK 365 
Abello, Horsholm, Denmark) were administered in theclinic and included an induction phase with 366 
increasing dosing starting with a dose of 20 SQ. The maintenance phase dose was 100 000 SQ. Six 367 
subjects discontinued the study before the last follow-up. Moreover, five out of the 16 subjects, who 368 
completed the study, had poor RNA quality in at least one nasal epithelial sample, leading to their 369 
exclusion. Thus, a total of 11 subjects (five healthy controls, three AR-AIT, and three AR-noAIT) 370 
completed the study. These participants were adults and of white European ancestry except one 371 
Chinese male at AR-noAIT group. 372 
 373 
FIG E2. Allergy related pathways identified in the pathway analysis. Gene expression profiles of 374 
A) asthma, B) toll like receptor (TLR) signaling, and C) chemokine signaling pathways among allergic 375 
rhinitis (AR) patients with pollen allergen immunotherapy (AIT), AR patients without AIT, and control 376 
subjects. Boxes in the figure represent genes. The gradient colors indicate the log2 fold-change of the 377 
gene between the spring samplings in AR-AIT (I/left), AR-noAIT (II/middle) and control (III/right) 378 
groups. Fold-change values beyond the range (from -2 to 2) were truncated to the closest extreme, i.e. 379 
values >2 were truncated to 2, and values < -2 truncated to -2. Asterisk indicates statistically significant 380 
difference with a Q-value ≤ 0.10. Green gradient colors indicate up-regulation of the gene at the second 381 














FIG E3. Landscape of expressed variants in allergic rhinitis. Short non-synonymous transcript 384 
variants identified in at least two AR (allergic rhinitis) but in none of the control cases. Variants are385 
grouped by gene. Column annotations from top to bottom: subject group, sampling season, and 386 
sampling year. Bar-plot at the right indicate the av r ge expression level of the gene in AR and control 387 
subjects expressed as counts per million (CPM). 388 
 389 
FIG E4. Microbial variation. A) Relative abundances of microbial (archaeal, bacterial, and viral) 390 
genera and total microbial load per sample. Only genera accounting for >5% of the total microbial load 391 
are shown. The line denotes the total number of microb al reads per sample expressed as counts per 392 
million (CPM). B) Principal coordinates analysis plot of microbial community structure based on Bray-393 
Curtis distance. C) A heat map of differentially abundant microbial species (Q-value ≤ 0.05) between 394 
any season- and group -matched year comparison. The different shades of blue illustrate the variance 395 
stabilizing transformation (VST) values. Darker shades of blue indicate higher values. The species 396 
were hierarchically clustered using average linkage nd distance metric Pearson correlation. Acronym 397 
S1 in the sample name stands for first spring (May), S2 for the second spring, W1 for the first winter 398 
(November), and W2 for the second winter. Comparisons that reached the statistical significance are 399 
indicated by black boxes next to the heatmap. 400 
 401 
FIG E5. Alpha diversity of epithelial microbiotas across study groups during winter and spring. 402 
Alpha diversity indices of different sample groups using a variety of alpha diversity metrics. Shown in 403 
the figure are alpha diversities computed using Shannon (A, B), ACE (C, D), Chao1 (E, F), observed 404 
(G, H), Fisher (I, J), InvSimpson (K, L), and Simpson (M, N) metrics with (B, D, F, H, J, L, N) and 405 
without (A, C, E, G, I, K, M) rarefaction of samples to the minimum sampling depth. In the figure, 406 
Nov1 stands for the first winter, Nov2 for the second winter, May1 for the first spring, and May2 for 407 
the second spring sampling point. 408 
 409 
FIG E6. Alpha diversity of epithelial microbiotas between groups during winter. Alpha diversity 410 
indices of different groups during two consecutive winters using a variety of alpha diversity metrics. 411 
Shown in the figure are alpha diversities computed using Shannon (A, B), ACE (C, D), Chao1 (E, F), 412 













N) and without (A, C, E, G, I, K, M) rarefaction ofsamples to the minimum sampling depth. In the 414 
figure, Nov1 stands for the first winter and Nov2 for the second winter sampling point. 415 
 416 
FIG E7. Alpha diversity of epithelial microbiotas between groups during spring. Alpha diversity 417 
indices of different groups during two consecutive springs sampling using a variety of alpha diversity 418 
metrics. Shown in the figure are alpha diversities computed using Shannon (A, B), ACE (C, D), Chao1 419 
(E, F), observed (G, H), Fisher (I, J), InvSimpson (K, L), and Simpson (M, N) metrics with (B, D, F, H420 
J, L, N) and without (A, C, E, G, I, K, M) rarefaction of samples to the minimum sampling depth. In 421 
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